GlassScriptPhysician profile
Leah Valvano
NPI 1124793864
$1,148.04
in general payments reported to CMS, 2019-2025
25 companies · $44.35 in 2025
The $44.35 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $298 · 2024: $806 · 2025: $44.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $154.91 | 2024 | Nayzilam, Zilbrysq, Rystiggo |
| Abbvie INC. | $149.74 | 2022-2024 | |
| Medtronic, INC. | $80.64 | 2024-2025 | Minimed 780g |
| Argenx US, INC. | $75.60 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $71.58 | 2024-2025 | Otezla, Enbrel, Krystexxa |
| Madrigal Pharmaceuticals | $65.95 | 2024 | Resmetirom |
| Mayne Pharma Commercial LLC | $64.98 | 2022 | |
| Inspire Medical Systems, INC. | $56.97 | 2024 | Inspire |
| Corcept Therapeutics | $47.41 | 2024 | Korlym |
| Lundbeck LLC | $46.74 | 2024 | Vyepti |
| Mannkind Corporation | $34.93 | 2024 | |
| Gilead Sciences, INC. | $29.95 | 2024 | |
| Evofem Biosciences, INC. | $29.78 | 2022 | |
| Pfizer INC. | $29.76 | 2022-2024 | |
| Dynavax Technologies Corporation | $26.88 | 2024 | Heplisav-B |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $23.23 | 2024 | Austedo Xr |
| Myovant Sciences INC. | $22.18 | 2022 | |
| Shield Therapeutics INC | $22.05 | 2022 | |
| Ascendis Pharma Endocrinology INC | $20.65 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.49 | 2024 | Gvoke Hypopen |
| Novo Nordisk INC | $16.12 | 2024 | Wegovy |
| Hologic Sales and Service, LLC | $15.95 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.80 | 2024 | |
| Lilly USA, LLC | $14.64 | 2024 | Zepbound, Jardiance |
| Exeltis, USA INC. | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Valvano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.